Antibody drug-conjugates targeting the tumor vasculature: Current and future developments

AUTOR(ES)

Gerber, Hans-Peter

FONTE

Landes Bioscience

RESUMO

Reducing the blood supply of tumors is one modality to combat cancer. Monoclonal antibodies are now established as a key therapeutic approach for a range of diseases. Owing to the ability of antibodies to selectively target endothelial cells within the tumor vasculature, vascular targeting programs have become a mainstay in oncology drug development. However, the antitumor activity of single agent administration of conventional anti-angiogenic compounds is limited and the improvements in patient survival are most prominent in combinations with chemotherapy. Furthermore, prolonged treatment with conventional anti-angiogenic drugs is associated with toxicity and drug resistance. These circumstances provide a strong rationale for novel approaches to enhance the efficacy of mAbs targeting tumor vasculature such as antibody-drug conjugates (ADCs). Here, we review trends in the development of ADCs targeting tumor vasculature with the aim of informing future research and development of this class of therapeutics.

Documentos Relacionados

• Autonomic neuromuscular junctions: current developments and future directions.
• Drug targeting: synthesis and endocytosis of oligonucleotide-neoglycoprotein conjugates.
• Current approaches and future developments in automatic tachycardia detection and diagnosis.
• Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier.
• Current and potential future drug treatments for osteoporosis.